+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Dementia Drugs Market by Drug Class, Distribution Channel, End User, Treatment Type, Route Of Administration, Patient Age Group, Disease Stage, Patent Status - Global Forecast 2025-2030- Product Image
Dementia Drugs Market by Drug Class, Distribution Channel, End User, Treatment Type, Route Of Administration, Patient Age Group, Disease Stage, Patent Status - Global Forecast 2025-2030- Product Image
Sale

Dementia Drugs Market by Drug Class, Distribution Channel, End User, Treatment Type, Route Of Administration, Patient Age Group, Disease Stage, Patent Status - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 196 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6083640
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The dementia drugs market is undergoing significant transformation as advances in research, clinical care models, and evolving global health priorities converge to reshape treatment landscapes. Senior decision-makers navigating this complex sector must track regulatory changes, market segmentation, and technological developments to drive effective strategy.

Market Snapshot: Dementia Drugs Market Growth and Evolving Dynamics

The Dementia Drugs Market grew from USD 10.78 billion in 2024 to USD 11.96 billion in 2025. It is expected to continue growing at a CAGR of 10.47%, reaching USD 19.60 billion by 2030. This robust trajectory reflects a confluence of factors: increased life expectancy, demographic shifts, and continuous innovation across drug development pipelines. Breakthroughs in disease-modifying therapies, enhanced diagnostic precision, and evolving regulatory policies are all shaping a dynamic market landscape with rising strategic opportunities for industry stakeholders.

Scope & Segmentation: Comprehensive View of the Dementia Drugs Market

  • Drug Classes: Includes cholinesterase inhibitors (donepezil, galantamine, rivastigmine), combination therapies (donepezil and memantine), and NMDA receptor antagonists (memantine).
  • Distribution Channels: Hospital pharmacy, retail pharmacy, specialty pharmacy, and online pharmacy channels enable product accessibility and influence care delivery models.
  • End Users: Targeted facilities and groups such as hospitals, clinics, home care settings, and long-term care facilities each present distinct engagement models and prescription trends.
  • Treatment Types: Both monotherapy and combination therapy approaches are utilized to meet diverse patient needs and clinical pathways.
  • Routes of Administration: Products are administered orally or via transdermal systems, responding to patient preferences and adherence requirements.
  • Patient Age Groups: Segments include under 65, 65 to 74, 75 to 84, and 85 and above, reflecting unique patient profiles and care priorities.
  • Disease Stages: Strategies differ across mild, moderate, and severe presentations, shaping portfolio development and clinical trial design.
  • Patent Status: The market covers branded and generic therapies, influencing competitive positioning and lifecycle management.
  • Regional Breakdown: Spanning Americas (including U.S., Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (UK, Germany, France, and others), and Asia-Pacific (China, India, Japan, Australia, South Korea, and more).
  • Industry Players: Key companies analyzed include Eisai Co., Ltd., Eli Lilly and Company, Novartis AG, H. Lundbeck A/S, AC Immune SA, Axsome Therapeutics, Cassava Sciences, Otsuka Pharmaceutical, Johnson & Johnson, and Merck & Co., Inc.

Dementia Drugs Market: Key Takeaways for Decision-Makers

  • Market growth remains driven by scientific advances from symptomatic therapies toward innovative disease-modifying and precision-targeted approaches.
  • Biomarker discovery and imaging technologies are supporting earlier diagnosis and improved patient stratification, influencing both research focus and commercial strategies.
  • Digital health tools, including remote monitoring and wearable sensors, increase patient engagement, support decentralized clinical trials, and streamline data collection.
  • Collaborative partnerships between pharmaceutical companies, academic institutions, and biotech firms accelerate discovery and risk-sharing across the value chain.
  • Patient-centric solutions and adaptive regulatory frameworks are critical for aligning drug access with positive clinical outcomes and sustainable pricing models.
  • Regional differences in infrastructure, reimbursement models, and regulatory environments require tailored go-to-market strategies and localized stakeholder engagement.

Tariff Impact: United States Trade Policies Shaping Market Costs and Access

Recent U.S. tariff policy has raised costs for key pharmaceutical ingredients and finished dementia therapies. Companies are adjusting operations by diversifying suppliers, optimizing procurement, and building domestic partnerships. These actions are designed to preserve margin stability, maintain supply continuity, and adapt pricing models to reimbursement shifts, while also expanding patient support and strengthening digital distribution solutions. Academic and clinical research centers are also rebalancing trial designs to accommodate increased cost volatility and logistical constraints, prompting a broader realignment of supply chain resilience strategies.

Methodology & Data Sources

This analysis combines comprehensive secondary data review, including published literature, clinical registries, and industry filings, with validation through expert interviews. Insights were triangulated across databases and stakeholder perspectives to ensure accuracy and contextual depth, strengthened by iterative validation workshops with clinical, regulatory, and supply chain experts.

Why This Report Matters

  • Deliver actionable intelligence for optimizing R&D investments, market entry, and commercialization across the dementia drugs market.
  • Empower strategic planning with insights on key technology trends, therapeutic innovations, and the evolving regulatory context.
  • Support resource allocation and risk management by anticipating the impact of new trade policies, regional diversity, and supply chain challenges.

Conclusion

The dementia drugs market continues to transform through clinical innovation, adaptive regulation, and responsive business models. Informed strategy and agile execution are essential for capturing opportunity and delivering long-term value in this complex therapeutic landscape.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Advances in amyloid-beta targeted monoclonal antibody therapies improving cognitive outcomes
5.2. Growth of combination therapies targeting tau proteins and neuroinflammation in Alzheimer’s disease
5.3. Expansion of diagnosis rates through blood-based biomarkers facilitating early intervention in dementia patients
5.4. Rising investment in gene therapy approaches aiming to modify APOE expression in dementia treatment
5.5. Emergence of digital therapeutics using AI-driven cognitive training platforms for dementia management
5.6. Increased regulatory approvals of disease-modifying therapies shifting Alzheimer’s treatment paradigms
5.7. Development of personalized medicine strategies based on patients’ genetic and biomarker profiles
5.8. Focus on gut-brain axis interventions exploring microbiome modulation to slow neurodegeneration in dementia
5.9. Implementation of remote patient monitoring tools for tracking cognitive decline in real time at scale
5.10. Collaborations between pharmaceutical and technology companies driving innovation in dementia drug pipelines
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Dementia Drugs Market, by Drug Class
8.1. Introduction
8.2. Cholinesterase Inhibitors
8.2.1. Donepezil
8.2.2. Galantamine
8.2.3. Rivastigmine
8.3. Combination Therapies
8.3.1. Donepezil And Memantine
8.4. Nmda Receptor Antagonists
8.4.1. Memantine
9. Dementia Drugs Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
9.5. Specialty Pharmacy
10. Dementia Drugs Market, by End User
10.1. Introduction
10.2. Clinics
10.3. Home Care Settings
10.4. Hospitals
10.5. Long-Term Care Facilities
11. Dementia Drugs Market, by Treatment Type
11.1. Introduction
11.2. Combination Therapy
11.3. Monotherapy
12. Dementia Drugs Market, by Route Of Administration
12.1. Introduction
12.2. Oral
12.3. Transdermal
13. Dementia Drugs Market, by Patient Age Group
13.1. Introduction
13.2. 65 To 74
13.3. 75 To 84
13.4. 85 And Above
13.5. Under 65
14. Dementia Drugs Market, by Disease Stage
14.1. Introduction
14.2. Mild
14.3. Moderate
14.4. Severe
15. Dementia Drugs Market, by Patent Status
15.1. Introduction
15.2. Branded
15.3. Generic
16. Americas Dementia Drugs Market
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. Argentina
17. Europe, Middle East & Africa Dementia Drugs Market
17.1. Introduction
17.2. United Kingdom
17.3. Germany
17.4. France
17.5. Russia
17.6. Italy
17.7. Spain
17.8. United Arab Emirates
17.9. Saudi Arabia
17.10. South Africa
17.11. Denmark
17.12. Netherlands
17.13. Qatar
17.14. Finland
17.15. Sweden
17.16. Nigeria
17.17. Egypt
17.18. Turkey
17.19. Israel
17.20. Norway
17.21. Poland
17.22. Switzerland
18. Asia-Pacific Dementia Drugs Market
18.1. Introduction
18.2. China
18.3. India
18.4. Japan
18.5. Australia
18.6. South Korea
18.7. Indonesia
18.8. Thailand
18.9. Philippines
18.10. Malaysia
18.11. Singapore
18.12. Vietnam
18.13. Taiwan
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Eisai Co., Ltd.
19.3.2. Eli Lilly and Company
19.3.3. Novartis AG
19.3.4. H. Lundbeck A/S
19.3.5. AC Immune SA
19.3.6. Axsome Therapeutics, Inc.
19.3.7. Cassava Sciences, Inc.
19.3.8. Otsuka Pharmaceutical Co., Ltd.
19.3.9. Johnson & Johnson
19.3.10. Merck & Co., Inc.
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. DEMENTIA DRUGS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL DEMENTIA DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2030 (%)
FIGURE 6. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 16. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 24. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. ASIA-PACIFIC DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. DEMENTIA DRUGS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 30. DEMENTIA DRUGS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 31. DEMENTIA DRUGS MARKET: RESEARCHAI
FIGURE 32. DEMENTIA DRUGS MARKET: RESEARCHSTATISTICS
FIGURE 33. DEMENTIA DRUGS MARKET: RESEARCHCONTACTS
FIGURE 34. DEMENTIA DRUGS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. DEMENTIA DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DEMENTIA DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL DEMENTIA DRUGS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DONEPEZIL, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DONEPEZIL, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GALANTAMINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GALANTAMINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RIVASTIGMINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DONEPEZIL AND MEMANTINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DONEPEZIL AND MEMANTINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MEMANTINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MEMANTINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 65 TO 74, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 65 TO 74, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 75 TO 84, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 75 TO 84, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 85 AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY 85 AND ABOVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY UNDER 65, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY UNDER 65, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MILD, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MILD, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MODERATE, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY MODERATE, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SEVERE, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY SEVERE, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY BRANDED, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL DEMENTIA DRUGS MARKET SIZE, BY GENERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 93. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 94. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 95. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 96. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 97. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 98. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 99. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 100. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 101. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 102. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 103. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 104. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 105. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 106. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 107. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 108. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 109. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2024 (USD MILLION)
TABLE 110. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2025-2030 (USD MILLION)
TABLE 111. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 112. AMERICAS DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 113. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 114. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 115. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 116. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 117. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 118. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 119. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 120. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 121. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 122. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 123. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 124. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 125. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 126. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 127. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 128. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 129. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 130. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 131. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 132. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 133. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2024 (USD MILLION)
TABLE 134. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2025-2030 (USD MILLION)
TABLE 135. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 136. UNITED STATES DEMENTIA DRUGS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 137. CANADA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 138. CANADA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 139. CANADA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 140. CANADA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 141. CANADA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 142. CANADA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 143. CANADA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 144. CANADA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 145. CANADA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. CANADA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. CANADA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. CANADA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. CANADA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 150. CANADA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 151. CANADA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 152. CANADA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 153. CANADA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 154. CANADA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 155. CANADA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 156. CANADA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 157. CANADA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2024 (USD MILLION)
TABLE 158. CANADA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2025-2030 (USD MILLION)
TABLE 159. MEXICO DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 160. MEXICO DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 161. MEXICO DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 162. MEXICO DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 163. MEXICO DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 164. MEXICO DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 165. MEXICO DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 166. MEXICO DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 167. MEXICO DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 168. MEXICO DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 169. MEXICO DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. MEXICO DEMENTIA DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. MEXICO DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 172. MEXICO DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 173. MEXICO DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 174. MEXICO DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 175. MEXICO DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 176. MEXICO DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 177. MEXICO DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 178. MEXICO DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 179. MEXICO DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2024 (USD MILLION)
TABLE 180. MEXICO DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2025-2030 (USD MILLION)
TABLE 181. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 182. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 183. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 184. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 185. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 186. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 187. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 188. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 189. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 190. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 191. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 192. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 193. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 194. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 195. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 196. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 197. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 198. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 199. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 200. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 201. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2024 (USD MILLION)
TABLE 202. BRAZIL DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2025-2030 (USD MILLION)
TABLE 203. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 204. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 205. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 206. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 207. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 208. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 209. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 210. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 211. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 212. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 213. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 216. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 217. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 218. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 219. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 220. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 221. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 222. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 223. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2024 (USD MILLION)
TABLE 224. ARGENTINA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2025-2030 (USD MILLION)
TABLE 225. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 226. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 227. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 228. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 229. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 230. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 231. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 232. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 233. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 234. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 235. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 236. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 237. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 238. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 239. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 240. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 241. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 242. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 243. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 244. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 245. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2024 (USD MILLION)
TABLE 246. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2025-2030 (USD MILLION)
TABLE 247. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 248. EUROPE, MIDDLE EAST & AFRICA DEMENTIA DRUGS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 249. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 250. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 251. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 252. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 253. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 254. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 255. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 256. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 257. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 258. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 259. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 262. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 263. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 264. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 265. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 266. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 267. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 268. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 269. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2024 (USD MILLION)
TABLE 270. UNITED KINGDOM DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2025-2030 (USD MILLION)
TABLE 271. GERMANY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 272. GERMANY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 273. GERMANY DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 274. GERMANY DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 275. GERMANY DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 276. GERMANY DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 277. GERMANY DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 278. GERMANY DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 279. GERMANY DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 280. GERMANY DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 281. GERMANY DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. GERMANY DEMENTIA DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. GERMANY DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 284. GERMANY DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 285. GERMANY DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 286. GERMANY DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 287. GERMANY DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 288. GERMANY DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 289. GERMANY DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 290. GERMANY DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 291. GERMANY DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2024 (USD MILLION)
TABLE 292. GERMANY DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2025-2030 (USD MILLION)
TABLE 293. FRANCE DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 294. FRANCE DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 295. FRANCE DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 296. FRANCE DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 297. FRANCE DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 298. FRANCE DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 299. FRANCE DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 300. FRANCE DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 301. FRANCE DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 302. FRANCE DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 303. FRANCE DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 304. FRANCE DEMENTIA DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 305. FRANCE DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 306. FRANCE DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 307. FRANCE DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 308. FRANCE DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 309. FRANCE DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 310. FRANCE DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 311. FRANCE DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 312. FRANCE DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 313. FRANCE DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2024 (USD MILLION)
TABLE 314. FRANCE DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2025-2030 (USD MILLION)
TABLE 315. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 316. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 317. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 318. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 319. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 320. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 321. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 322. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2025-2030 (USD MILLION)
TABLE 323. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 324. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 325. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 326. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 327. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 328. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 329. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 330. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 331. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 332. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 333. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2018-2024 (USD MILLION)
TABLE 334. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY DISEASE STAGE, 2025-2030 (USD MILLION)
TABLE 335. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2018-2024 (USD MILLION)
TABLE 336. RUSSIA DEMENTIA DRUGS MARKET SIZE, BY PATENT STATUS, 2025-2030 (USD MILLION)
TABLE 337. ITALY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
TABLE 338. ITALY DEMENTIA DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2030 (USD MILLION)
TABLE 339. ITALY DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2018-2024 (USD MILLION)
TABLE 340. ITALY DEMENTIA DRUGS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, 2025-2030 (USD MILLION)
TABLE 341. ITALY DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2018-2024 (USD MILLION)
TABLE 342. ITALY DEMENTIA DRUGS MARKET SIZE, BY COMBINATION THERAPIES, 2025-2030 (USD MILLION)
TABLE 343. ITALY DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS, 2018-2024 (USD MILLION)
TABLE 344. ITALY DEMENTIA DRUGS MARKET SIZE, BY NMDA RECEPTOR ANTAGONISTS,

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Dementia Drugs market report include:
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Novartis AG
  • H. Lundbeck A/S
  • AC Immune SA
  • Axsome Therapeutics, Inc.
  • Cassava Sciences, Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.

Table Information

Report AttributeDetails
No. of Pages196
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.96 Billion
Forecasted Market Value ( USD ) by 2030 $ 19.6 Billion
Compound Annual Growth Rate10.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Dementia Treatment Market Size, Share & Trends Analysis Report by Indication, Drug Class, Route of Administration (Oral, Transdermal Patch, Injectable), Distribution Channel, and Region with Growth Forecasts, 2025-2030 - Product Image

Dementia Treatment Market Size, Share & Trends Analysis Report by Indication, Drug Class, Route of Administration (Oral, Transdermal Patch, Injectable), Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Dementia Drugs Market Report and Forecast 2025-2034 - Product Image

Dementia Drugs Market Report and Forecast 2025-2034

  • Report
  • 400 Pages
  • Global
From
Dementia Drugs Market by Indication, Drug Class, Distribution Channel, and Region 2025-2033 - Product Image

Dementia Drugs Market by Indication, Drug Class, Distribution Channel, and Region 2025-2033

  • Report
  • 134 Pages
  • Global
From
Lewy Body Dementia Treatment Market by Treatment Modality (Non Pharmacological, Pharmacological), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End User, Route Of Administration, Treatment Line - Global Forecast 2025-2030 - Product Image

Lewy Body Dementia Treatment Market by Treatment Modality (Non Pharmacological, Pharmacological), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies), End User, Route Of Administration, Treatment Line - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
Dementia Drugs - Global Strategic Business Report - Product Image

Dementia Drugs - Global Strategic Business Report

  • Report
  • 286 Pages
  • Global
From

About the Market

The Dementia Drug market is a subset of the Central Nervous System Drugs market, which includes drugs used to treat neurological disorders. Dementia drugs are used to treat the cognitive decline associated with Alzheimer's disease, vascular dementia, and other forms of dementia. These drugs are typically prescribed to improve memory, thinking, and behavior, as well as to slow the progression of the disease. Common dementia drugs include cholinesterase inhibitors, memantine, and glutamate modulators. Some companies in the Dementia Drug market include Pfizer, Novartis, Merck, and Eli Lilly. Other companies include Biogen, AstraZeneca, and Johnson & Johnson. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.